Table 3 Proportion of reviewers reporting CTE-NC for each slide and primary antibody
| Â | Tau antibody | |||
|---|---|---|---|---|
Case No | 3R | GT-38 | 4R | PHF-1 |
All sections | 28% | 57% | 74% | 79% |
CTE-NC | ||||
All sections | 5% | 43% | 70% | 75% |
1 | 0 | 33% | 56% | 44% |
2 | 0 | 56% | 78% | 89% |
3 | 22% | 0 | 100% | 11% |
4 | 11% | 22% | 78% | 78% |
5 | 0 | 44% | 100% | 100% |
6 | 11% | 33% | 67% | 100% |
7 | 0 | 78% | 44% | 100% |
8 | 0 | 67% | 44% | 67% |
9 | 0 | 11% | 56% | 100% |
10 | 0 | 78% | 100% | 89% |
11 | 11% | 89% | 100% | 100% |
12 | 0 | 0 | 22% | 22% |
ADNC | ||||
All sections | 3% | 0 | 17% | 8% |
13 | 0 | 0 | 0 | 0 |
14 | 0 | 0 | 56% | 11% |
15 | 0 | 0 | 11% | 11% |
16 | 11% | 0 | 0% | 11% |